The EuroFlow™ strategy to monitor minimal residual disease (MRD) by Next Generation Flow has been focused in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) patients.

The BCP-ALL MRD kit, designed following the fully-standardized EuroFlow™ 8-color antibody panel, allows measuring MRD and discriminating between normal and malignant BCP cells in 99% of studied BCP-ALL patients.

Protected by patent
Pacific Blue™ is a trademark of Life Technologies Corporation